Using Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

Joshua Richter, MD, gives an overview of treatment options in multiple myeloma and factors that influence treatment decisions.

Expert oncologist Joshua Richter, MD, defines triple-class refractory multiple myeloma and describes selinexor’s unique mechanism of action.

An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.

An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.

Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.

Joshua Richter, MD, discusses the optimal use of selinexor in the treatment of relapsed/refractory multiple myeloma.